Related Experiment Videos
Coumadin-induced hepatitis
Anna Leikin1, Monir Merei, Eyal Dahan
1Department of Internal Medicine A, Poria Medical Center, Lower Galilee 15208, Israel.
European Journal of Internal Medicine
|March 1, 2005
Summary
Coumadin-induced hepatitis, though rare, is diagnosed by drug timing, improvement after stopping, recurrence upon re-exposure, and liver biopsy. This drug-induced liver injury often mimics viral hepatitis.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Hepatotoxicity from coumadin derivatives is an uncommon but significant concern.
- Drug-induced liver injury (DILI) can present with varied clinical and histological features.
Purpose of the Study:
- To highlight the diagnostic criteria for coumadin-induced hepatitis.
- To emphasize the importance of recognizing the hepatotoxic potential of coumadin derivatives.
Main Methods:
- Case analysis focusing on temporal association between coumadin initiation and liver dysfunction.
- Evaluation of response to drug withdrawal and challenge.
- Review of liver histology findings.
Main Results:
- The diagnosis is supported by the timing of drug administration and symptom onset.
- Rapid improvement of liver function after discontinuing coumadin was observed.
- Recurrence of liver dysfunction upon re-administration of the drug confirmed causality.
- Liver histology can provide supporting evidence.
Conclusions:
- Coumadin-induced hepatitis is a viable diagnosis when clinical and histological features align with drug exposure.
- Awareness of coumadin's hepatotoxic potential is crucial for clinicians, as it can mimic viral hepatitis.
- Early recognition and drug withdrawal are key to managing this rare adverse effect.